Kinnate Biopharma (KNTE) Stock Forecast, Price Target & Predictions
KNTE Stock Forecast
Kinnate Biopharma stock forecast is as follows: an average price target of $30.00 (represents a 1032.08% upside from KNTE’s last price of $2.65) and a rating consensus of 'Hold', based on 3 wall street analysts offering a 1-year stock forecast.
KNTE Price Target
KNTE Analyst Ratings
Hold
Kinnate Biopharma Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
May 18, 2022 | Christopher Raymond | Piper Sandler | $30.00 | $9.96 | 201.20% | 1032.08% |
10
Kinnate Biopharma Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | - |
Avg Price Target | - | - | - |
Last Closing Price | $2.65 | $2.65 | $2.65 |
Upside/Downside | -100.00% | -100.00% | -100.00% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Sep 19, 2023 | Piper Sandler | Overweight | Neutral | Downgrade |
Sep 19, 2023 | Wedbush | - | Neutral | Downgrade |
May 18, 2022 | Piper Sandler | Overweight | Overweight | Hold |
Mar 29, 2022 | William Blair | Outperform | Outperform | Hold |
10
Kinnate Biopharma Financial Forecast
Kinnate Biopharma Revenue Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - | - | - |
# Analysts | - | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - | - |
Forecast
Kinnate Biopharma EBITDA Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - | - |
Forecast
Kinnate Biopharma Net Income Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | - | - |
Net Income | - | - | - | - | - | - | - | - | - |
Avg Forecast | $-8.95M | $-8.95M | $-12.25M | $-12.25M | $-9.42M | $-13.67M | $-13.67M | $-13.67M | $-20.03M |
High Forecast | $-8.95M | $-8.95M | $-12.25M | $-12.25M | $-9.42M | $-13.67M | $-13.67M | $-11.01M | $-16.47M |
Low Forecast | $-8.95M | $-8.95M | $-12.25M | $-12.25M | $-9.42M | $-13.67M | $-13.67M | $-16.32M | $-22.25M |
Surprise % | - | - | - | - | - | - | - | - | - |
Forecast
Kinnate Biopharma SG&A Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | - | - |
SG&A | - | - | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - | - |
Forecast
Kinnate Biopharma EPS Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | - | - |
EPS | - | - | - | - | - | - | - | - | - |
Avg Forecast | $-0.19 | $-0.19 | $-0.26 | $-0.26 | $-0.20 | $-0.29 | $-0.29 | $-0.29 | $-0.42 |
High Forecast | $-0.19 | $-0.19 | $-0.26 | $-0.26 | $-0.20 | $-0.29 | $-0.29 | $-0.23 | $-0.35 |
Low Forecast | $-0.19 | $-0.19 | $-0.26 | $-0.26 | $-0.20 | $-0.29 | $-0.29 | $-0.35 | $-0.47 |
Surprise % | - | - | - | - | - | - | - | - | - |
Forecast
Kinnate Biopharma Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
IPSC | Century Therapeutics | $1.24 | $15.00 | 1109.68% | Buy |
KNTE | Kinnate Biopharma | $2.65 | $30.00 | 1032.08% | Hold |
PASG | Passage Bio | $0.54 | $6.00 | 1011.11% | Buy |
CCCC | C4 Therapeutics | $4.01 | $13.50 | 236.66% | Buy |
LRMR | Larimar Therapeutics | $6.13 | $20.33 | 231.65% | Buy |
FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
STOK | Stoke Therapeutics | $11.27 | $30.60 | 171.52% | Buy |
ERAS | Erasca | $2.60 | $6.50 | 150.00% | Buy |
SLRN | Acelyrin | $4.33 | $10.50 | 142.49% | Buy |
KZR | Kezar Life Sciences | $7.62 | $17.50 | 129.66% | Buy |
KROS | Keros Therapeutics | $53.84 | $102.60 | 90.56% | Buy |
KRON | Kronos Bio | $0.87 | $1.63 | 87.36% | Buy |
BOLT | Bolt Biotherapeutics | $0.57 | $1.00 | 75.44% | Hold |
DSGN | Design Therapeutics | $5.57 | $9.67 | 73.61% | Buy |
EWTX | Edgewise Therapeutics | $31.98 | $45.00 | 40.71% | Buy |
PALI | Palisade Bio | $2.44 | $1.50 | -38.52% | Buy |
GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |